Celgene Corporation (CELG) : Artal Group S.a. scooped up 260,000 additional shares in Celgene Corporation during the most recent quarter end , the firm said in a disclosure report filed with the SEC on May 12, 2016. The investment management firm now holds a total of 360,000 shares of Celgene Corporation which is valued at $36.1 Million.Celgene Corporation makes up approximately 0.78% of Artal Group S.a.’s portfolio.
Other Hedge Funds, Including , Canada Pension Plan Investment Board boosted its stake in CELG in the latest quarter, The investment management firm added 127,911 additional shares and now holds a total of 160,810 shares of Celgene Corporation which is valued at $16.1 Million. Celgene Corporation makes up approx 0.07% of Canada Pension Plan Investment Board’s portfolio.Willingdon Wealth Management reduced its stake in CELG by selling 2,000 shares or 20.41% in the most recent quarter. The Hedge Fund company now holds 7,798 shares of CELG which is valued at $781,048. Celgene Corporation makes up approx 0.48% of Willingdon Wealth Management’s portfolio.First National Bank Of Hutchinson boosted its stake in CELG in the latest quarter, The investment management firm added 945 additional shares and now holds a total of 8,856 shares of Celgene Corporation which is valued at $887,017. Celgene Corporation makes up approx 0.57% of First National Bank Of Hutchinson’s portfolio.Asset Dedication reduced its stake in CELG by selling 54 shares or 4.62% in the most recent quarter. The Hedge Fund company now holds 1,114 shares of CELG which is valued at $115,199. Celgene Corporation makes up approx 0.08% of Asset Dedication’s portfolio.
Celgene Corporation opened for trading at $100.12 and hit $102.41 on the upside on Friday, eventually ending the session at $101.46, with a gain of 1.52% or 1.52 points. The heightened volatility saw the trading volume jump to 37,10,192 shares. Company has a market cap of $78,591,017 M.
On the company’s financial health, Celgene Corporation reported $1.32 EPS for the quarter, beating the analyst consensus estimate by $ 0.05 according to the earnings call on Apr 28, 2016. Analyst had a consensus of $1.27. The company had revenue of $2511.60 million for the quarter, compared to analysts expectations of $2577.08 million. The company’s revenue was up 20.7% compared to the same quarter last year. During the same quarter in the previous year, the company posted $1.07 EPS.
Many Wall Street Analysts have commented on Celgene Corporation. Company shares were Reiterated by Sun Trust Rbsn Humphrey on Apr 29, 2016 to “Buy”, Firm has raised the Price Target to $ 147 from a previous price target of $145 .Citigroup Initiated Celgene Corporation on Feb 25, 2016 to “Buy”, Price Target of the shares are set at $130.
Celgene Corporation (Celgene) together with its subsidiaries is an integrated biopharmaceutical company engaged primarily in the discovery development and commercialization of therapies for the treatment of cancer and inflammatory diseases through gene and protein regulation. The Companys primary commercial stage products include REVLIMID (lenalidomide) ABRAXANE POMALYST/IMNOVID VIDAZA azacitidine for injection (generic version of VIDAZA) THALOMID (sold as THALOMID or Thalidomide Celgene outside the United States) OTEZLA (apremilast) and ISTODAX (romidepsin). Celgene is involved in research in a range of scientific areas designed to deliver therapies targeting areas including intracellular signaling pathways protein homeostasis and epigenetics in cancer and immune cells immunomodulation in cancer and autoimmune diseases and therapeutic application of cell therapies.